Events
Primary care discussions: Hypertension care in community pharmacy
A community pharmacist, GP, and primary care team share how blood pressure management has strengthened Access and Recovery services and improved patient care.
Latest developments in Health and Justice Medicines Optimisation
Sharing the latest developments in Health and Justice medicines optimisation and pharmacy services.
Biosimilar and key generic medicines – December 2025 update
An update about biosimilar and key generic medicines to support system planning and mobilisation.
Standard operating procedures in pharmacy technical services
An SPS Quality Assurance (QA) bite size learning event on Standard Operating Procedures as part of the quality management system.
Guidance
New and updated articles published to the website during November 2025.
New guidance
Polypharmacy and structured medication review explainer videos
These animated videos explain the 7 steps of structured medication review, using a person-centred approach to managing polypharmacy
The licence and supporting evidence for denosumab 60mg biosimilars
Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
Ensuring the safe use of amphotericin B injection
Amphotericin B liposomal products and Fungizone are not interchangeable. Take action to prevent death caused by inadvertent mis-selection
Deriving and assessing stability data for medicines
Advice about undertaking stability studies and assessing the suitability of published studies
Ex-Vivo Non-GMO Gene Therapy Medicinal Products – Pharmacy Institutional Readiness Guidance
This document outlines key areas for focus of pharmacy expertise prior to an organisation implementing Ex-Vivo Non-Genetically Modified Organism Gene Therapies.
In-Vivo Non-GMO Gene Therapy Medicinal Products – Pharmacy Institutional Readiness Guidance
This document outlines key areas for focus of pharmacy expertise prior to an organisation implementing In-Vivo Non-Genetically Modified Organism Gene Therapies.
Updated guidance
Preparing to use denosumab 60mg biosimilar
Biosimilars of denosumab 60mg (Prolia) are expected soon. We offer general information and implementation advice.
Preparing to use denosumab 120mg biosimilar
Biosimilars of denosumab 120mg (Xgeva) are expected soon. We offer general information and implementation advice.
The licence and supporting evidence for omalizumab biosimilar
We highlight evidence for licensed omalizumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Xolair).
The licence and supporting evidence for ranibizumab biosimilars
Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
Preparing to use ranibizumab biosimilar
Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
Restricted to NHS: The licence and supporting evidence for aflibercept biosimilars
Aflibercept 2mg biosimilars Afqlir, Eydenzelt, Yesafili and Vgenfli are expected in December 2025 for NHS use. Learn about supporting evidence and differences.
Anticoagulant suggestions for adults with swallowing difficulties
A range of oral anticoagulant formulations are suitable for adults with swallowing difficulties.
Publications
Medication Safety Update
A resource collating the latest medication safety communications and publications to inform, support and inspire medication safety improvements.
New Medicines News
New Medicines News is produced by the SPS Horizon Scanning Service. It highlights recent new product launches and significant medicines regulatory changes.
Restricted to NHS: New Product Evaluations
A list of new product evaluations that are freely available to NHS staff.
PGDs
The following updated PGD and protocol templates have been published in advance to allow organisations to undertake local governance processes in a timely manner.
Ceftriaxone intramuscular injection for Neisseria gonorrhoeae
SPS PGD template for administering ceftriaxone injection (with lidocaine) by IM injection for treating uncomplicated Neisseria gonorrhoeae infection.
Ulipristal acetate 30mg tablets for emergency contraception
SPS PGD template for the supply and/or administration of ulipristal acetate 30mg tablet for emergency contraception.
Folic acid 5mg tablets for use during pregnancy
SPS PGD template for the supply of folic acid 5mg tablets to reduce risk of neural tube defect or compensate for increased folate demand during pregnancy.
Doxycycline for use within sexual health services
SPS PGD template for supply of doxycycline for the treatment of uncomplicated genital chlamydia trachomatis, LGV and non-gonococcal/non-specific urethritis.
Azithromycin (oral) for use within sexual health services
SPS PGD template for supply of azithromycin for uncomplicated genital Chlamydia trachomatis, non-gonococcal/non-specific urethritis; Mycoplasma genitalium.
Emtricitabine and tenofovir disoproxil (TD) tablets as PrEP
SPS PGD template for the supply of emtricitabine and tenofovir disoproxil (TD) tablets as Pre-Exposure Prophylaxis (PrEP) for the prevention of HIV infection.
Intrathecal risk assessments
The following intrathecal risk assessments have been reviewed and updated.
Diamorphine hydrochloride: informing intrathecal risk assessment
Diamorphine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Etoposide: informing intrathecal risk assessment
Etoposide products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Gentamicin: informing intrathecal risk assessment
Gentamicin products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Rituximab: informing intrathecal risk assessment
Rituximab products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Thiotepa: informing intrathecal risk assessment
Thiotepa products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Shortages
Prescribing available medicines to treat ADHD
The availability of medicines used to treat Attention Deficit Hyperactivity Disorder (ADHD) varies currently. Supply content is maintained regularly by DHSC.
Prescribing available HRT products
Hormone Replacement Therapy availability varies currently. Check for available products and keep up-to-date. Supply content is maintained regularly by DHSC.
Medicines Supply Tool
Latest information on supply issues, actions to take, alternatives to use, and expected resolution dates. Content provided by DHSC and MVA team, NHS England.